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Abstract
Dendritic cells (DCs) contribute to human immunodeficiency virus type 1 (HIV-1) transmission and dissemination by
capturing and transporting infectious virus from the mucosa to draining lymph nodes, and transferring these virus particles
to CD4+ T cells with high efficiency. Toll-like receptor (TLR)-induced maturation of DCs enhances their ability to mediate
trans-infection of T cells and their ability to migrate from the site of infection. Because TLR-induced maturation can be
inhibited by nuclear receptor (NR) signaling, we hypothesized that ligand-activated NRs could repress DC-mediated HIV-1
transmission and dissemination. Here, we show that ligands for peroxisome proliferator-activated receptor gamma (PPARc)
and liver X receptor (LXR) prevented proinflammatory cytokine production by DCs and inhibited DC migration in response
to the chemokine CCL21 by preventing the TLR-induced upregulation of CCR7. Importantly, PPARc and LXR signaling
inhibited both immature and mature DC-mediated trans-infection by preventing the capture of HIV-1 by DCs independent
of the viral envelope glycoprotein. PPARc and LXR signaling induced cholesterol efflux from DCs and led to a decrease in
DC-associated cholesterol, which has previously been shown to be required for DC capture of HIV-1. Finally, both
cholesterol repletion and the targeted knockdown of the cholesterol transport protein ATP-binding cassette A1 (ABCA1)
restored the ability of NR ligand treated cells to capture HIV-1 and transfer it to T cells. Our results suggest that PPARc and
LXR signaling up-regulate ABCA1-mediated cholesterol efflux from DCs and that this accounts for the decreased ability of
DCs to capture HIV-1. The ability of NR ligands to repress DC mediated trans-infection, inflammation, and DC migration
underscores their potential therapeutic value in inhibiting HIV-1 mucosal transmission.
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Introduction
Worldwide, heterosexual transmission accounts for most new
HIV-1 infections, with a majority of these occurring in developing
countries [1,2]. Clearly, controlling heterosexual transmission of
HIV-1 would be a significant step toward reducing this global
pandemic. To achieve this goal, it will be important to delineate
the cellular and molecular events that promote or restrict virus
transmission and dissemination.
Immune cells within the vaginal, cervical, or rectal mucosa are
thought to be the primary targets of infection in the sexual
transmission of HIV-1 [1,3,4]. These target cells include sub-
epithelial CD4+ T lymphocytes, intra-epithelial Langerhans cells,
macrophages, submucosal plasmacytoid DCs (pDCs), and myeloid
(or conventional) DCs (mDCs) located within the lamina propria
[4,5,6,7,8,9,10,11]. DCs, in particular, play a central role in HIV-
1 transmission. DCs are thought to capture cell-free HIV-1
particles from the intralumenal space or from the mucosa after
transcytosis across or leakage of HIV-1 particles through the
epithelial barrier or by contacting HIV-1-infected cells introduced
into the mucosa through abrasions or ulcerative lesions [6,12,13].
In addition, studies examining vaginal transmission of SIVmac in a
rhesus macaque model of AIDS have implicated DCs in virus
dissemination from the mucosa to draining lymph nodes [6,14].
Moreover, DCs are the predominant infected migratory cell type
harboring HIV-1 from virus exposed cervical tissue explants [15]
supporting the idea that they are involved in virus dissemination.
Upon capture, DCs can deliver infectious HIV-1particles to
draining lymph nodes that contain large numbers of CD4+ T cells
[16,17]. The close contact between virus-laden DCs and CD4+ T
cells facilitates cell-to-cell transmission and viral spread [18,19]. In
addition to their roles in virus transmission and dissemination,
DCs can produce proinflammatory cytokines that create a
microenvironment that favors virus replication [20,21,22]. Recent
reports have demonstrated that DCs matured by exposure to
pathogens encoding Toll-like receptor (TLR) ligands or to
proinflammatory cytokines are capable of enhanced HIV-1 trans-
infection [23,24,25] and chemokine-directed migration [26,27],
suggesting that agents capable of preventing inflammation and DC
maturation may be able to limit HIV-1 transmission and
dissemination.
NRs are a superfamily of ligand-activated transcription factors
that includes classic hormone receptors, as well as the so-called
orphan receptors and adopted orphan receptors whose natural
ligands are either unknown or recently discovered [28,29].
Included in these latter two families are peroxisome-proliferator
activated receptors (PPAR) and liver X receptors (LXR). Ligand-
activated PPARc and LXR are bifunctional modulators of gene
expression, capable of either activating or repressing transcription
in a promoter-specific manner. Importantly, PPARc and LXR are
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potent inhibitors of inflammation and are capable of repressing
cytokine and chemokine production by Toll-like receptor (TLR)-
activated macrophages and DCs through trans-repression mecha-
nisms involving the failure to clear co-repressor complexes from
promoters or through direct antagonism of transcription factors
such as the p65 subunit of NF-kB, AP-1, STATs, and IRF3
[30,31,32,33,34,35,36,37,38]. The effects of PPARc and LXR on
TLR signaling are complex and a number of studies have
demonstrated that each NR inhibits different subsets of inflam-
matory genes [32,34]. For example, LXR signaling represses
TLR4-induced expression of iNOS, COX-2, and IL-6 in murine
macrophages, while PPARc signaling represses IL-1b, GCSF,
MCP-1, MCP-3, and MIP-1a expression [32]. Here, we show that
PPARc and LXR signaling acutely prevents TLR-activated
expression of the proinflammatory cytokines TNF-a, IL-6, and
IL-8, which have been implicated as co-factors for enhanced
mucosal transmission of HIV-1. Moreover, PPARc and LXR
signaling inhibit the expression of the chemokine receptor CCR7,
thereby preventing DC chemotaxis in response to gradients of
CCL21, a process thought to be involved in DC migration from
mucosal surfaces to draining lymph nodes.
As opposed to their inhibitory effects on inflammatory gene
expression, ligand-activated PPARc and LXR induce expression
of genes involved in lipid and cholesterol metabolism, as well as
cholesterol transport, including ABCA1 and ABCG1
[29,39,40,41]. Importantly, many studies have demonstrated that
cholesterol plays an essential role in HIV-1 biology. Cholesterol
must be present in both the target cell membranes and HIV-1
particles for efficient virus binding and fusion [42,43,44,45,46]. In
addition, nascent HIV-1 particles bud through cholesterol-rich
lipid rafts [47,48] and infectious particles enter target cells through
cholesterol-rich lipid rafts [42,49,50]. Finally, studies using the
cholesterol chelator, methyl-b-cyclodextrin, demonstrated that
cholesterol is required for DC binding of virus particles [51].
Interestingly, PPARs and LXR are expressed at high levels in
HIV-1 target cells such as macrophages and DCs [28,29].
Therefore, we hypothesized that PPARc and LXR-mediated
changes in cholesterol metabolism and trafficking might contribute
to their ability to inhibit the transmission of HIV-1 from DCs to T
cells. Our results demonstrate that PPARc and LXR signaling
inhibit the capture of HIV-1 by DCs, and its subsequent transfer
to CD4+ T cells. These effects are due to up-regulation of ABCA1-
dependent cholesterol efflux, a mechanism distinct from the effects
of PPARc and LXR signaling on DC migration and proin-
flammatory cytokine production. Collectively, our data suggest
that the bifunctional activities of ligand activated PPARc and
LXR can be exploited to inhibit multiple distinct steps in HIV-1
mucosal transmission and dissemination.
Results
Treatment with PPARc and LXR ligands prevents the
maturation of MDDCs
TLR signaling induced by sexually transmitted pathogens is
thought to enhance HIV-1 mucosal transmission in part by
promoting local inflammation. Inflammation not only activates
HIV-1 target cells but, importantly, it also induces DC maturation
and the subsequent migration of HIV-1-carrying DCs to local
lymph nodes where they can contribute to virus dissemination
[16,17]. We were therefore interested in determining whether the
anti-inflammatory activities of ligand-activated PPARc and LXR
[34,52,53] could be exploited to limit DC functions involved in
HIV-1 transmission and pathogenesis. To examine the effects of
PPARc and LXR signaling on DC maturation, human monocyte-
derived DCs (MDDCs) were treated with E. coli K12 LPS, a TLR4
ligand, in the presence or absence of ligands for PPARc and LXR.
As expected, LPS treatment upregulated the expression of surface
markers associated with maturation, such as HLA-DR, CD80,
CD86, and CD83, downregulated the expression of surface
markers associated with an immature phenotype, such as the C-
type lectin DC-SIGN, but had no effect on the expression of the
pan-DC marker CD11c (Figure 1A and data not shown). Notably,
treatment of MDDCs with the PPARc ligand ciglitazone or the
LXR ligand TO-901317 inhibited LPS-dependent upregulation of
cell-surface expression of HLA-DR, CD80, and CD86 (Figure 1A).
Similarly, we found that ciglitazone or TO-901317 treatment
inhibited human MDDC maturation in response to the TLR2
ligand PAM3CSK4 (data not shown).
We next examined the effects of ciglitazone and TO-901317
treatment on TLR-induced proinflammatory cytokine and
chemokine production. We found that treatment with these
PPARc and LXR ligands prevented the release of proinflamma-
tory cytokines and chemokines such as TNF-a, IL-6, and IL-8 by
PAM3CSK4-activated MDDCs (Figure 1B). In addition, PPARc
and LXR treatment also prevented the release of the chemokines
MIP-1a and RANTES, which are important for the recruitment
of CD4+ T cells to sites of infection, both from MDDC in response
to the TLR4 ligand LPS (Figure 1C) and from plasmacytoid DCs
(pDCs) in response to the TLR7 ligand CLO97 and the TLR9
ligand CpG ODN 2006 (Figure 1D). Importantly, PPARc and
LXR signaling inhibited TLR-induced proinflammatory cytokine
and chemokine production coincident with TLR ligation (data not
shown), suggesting that NR-mediated inhibition most likely acts
through a trans-repression mechanism [34]. The concentrations of
the PPARc ligand ciglitazone and the LXR ligand TO-901317
necessary to see a reduction in DC maturation and the production
of pro-inflammatory cytokines and chemokines did not affect
MDDC viability as measured by LDH release or mitochondrial
activity (Figure S1 and data not shown).
Author Summary
Heterosexual transmission is the primary mode of HIV
transmission worldwide. In the absence of an effective
vaccine, there is an increasing demand for the develop-
ment of effective microbicides that block HIV sexual
transmission. Dendritic cells (DCs) play a critical role in
HIV transmission by efficiently binding virus particles,
migrating to lymph nodes, and transmitting them to CD4+
T cells, a process called trans-infection. In addition, DCs
secrete proinflammatory cytokines that create a favorable
environment for virus replication. DC maturation by
pathogen-encoded TLR ligands or proinflammatory cyto-
kines dramatically increases their capacity to capture HIV,
migrate to lymphoid tissue, and trans-infect T cells. Here,
we report that signaling through the nuclear receptors
PPARc and LXR prevents DC maturation and proinflam-
matory cytokine production, as well as migration. In
addition, PPARc and LXR signaling prevents efficient DC
capture and transfer of infectious HIV by increasing
ABCA1-mediated cholesterol efflux. Our studies suggest
that PPARc and LXR may be targets for drugs that can
inhibit specific aspects of HIV mucosal transmission,
namely inflammation, migration, and virus capture and
transfer. These findings provide a rationale for considering
PPARc and LXR agonists as potential combination
therapies with conventional anti-viral microbicides that
target other aspects of mucosal HIV transmission.
PPARc and LXR Inhibit DC-Mediated HIV-1 trans-Infection
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NR signaling prevents MDDC migration in response to
CCL21
In addition to transmitting HIV-1 to T cells with high efficiency,
DCs can also contribute to HIV-1 pathogenesis by binding virus
and then migrating frommucosal sites of infection to regional lymph
nodes. In this way, DCs can contribute to viral dissemination.
Studies have shown that mature DCs have a greater migratory
capacity than immature DCs [26,27]. This led us to examine
whether NR signaling would also inhibit MDDCmigration through
a 5 mm pore size Transwell insert in response to the chemokine
CCL21, which has been shown to be important for DCmigration in
vivo [27]. We found that LPS-matured MDDCs (mMDDCs)
migrated in response to a CCL21 gradient and that co-treatment
with PPARc or LXR ligands repressed this migration approxi-
mately 2-fold (Figure 2A). In contrast, immature MDDCs
(iMDDCs) migrated quite poorly in response to CCL21 and,
consequently, NR ligand treatment had a limited effect. Expression
of CCR7, a receptor for CCL21, is upregulated in DCs in response
to TLR engagement [26,54]. Notably, treatment with PPARc and
LXR ligands prevented the LPS-induced upregulation of CCR7
(Figure 2B), which may partly explain why NR ligand-treated
MDDCs migrate poorly in response to CCL21. Together, these
data suggest that PPARc and LXR signaling inhibit DC migration
by preventing TLR-induced DC maturation.
Figure 1. PPARc and LXR ligand treatment prevents MDDC maturation and pro-inflammatory cytokine production. (A) MDDCs were
treated with LPS for 48 hours in the presence or absence of the PPARc ligand ciglitazone (100 mM; upper panel) or the LXR ligand TO-901317 (1 mM;
lower panel). NR ligands were added one hour prior to TLR ligand addition. MDDCs were then stained for surface expression of HLA-DR, CD80, CD86,
and CD11c and analyzed by flow cytometry. Shaded histogram, isotype control. Black line, iMDDCs. Blue line, LPS-treated MDDCs. Red line, LPS and
nuclear receptor ligand-treated MDDCs. (B) MDDCs were treated with PAM3CSK4 in the presence or absence of 100 mM ciglitazone (upper panels) or
1 mM TO-901317 (lower panels). Cell-free supernatants were analyzed for TNF-a, IL-6, and IL-8 by ELISA. (n = 3) (C) MDDCs were treated with 100 ng/
ml LPS in the presence or absence of 100 mM ciglitazone or 1 mM TO-901317. Cell-free supernatants were analyzed for MIP-1a and RANTES. (n = 3) (D)
pDCs were treated with 5 mM CpG ODN 2006 or 1 mg/ml CLO97 in the presence or absence of 100 mM ciglitazone or 1 mM TO-901317. Cell-free
supernatants were analyzed for MIP-1a and RANTES. (n = 4). * p,0.001 compared to TLR ligand-treated controls; ND, not detected.
doi:10.1371/journal.ppat.1000981.g001
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NR ligands inhibit MDDC-mediated trans-infection of
HIV-1 to T cells
DCs are thought to play a critical role in virus dissemination by
capturing HIV-1 and transferring it to T cells [5,24,55]. We
therefore examined whether NR ligands could modulate DC-
mediated HIV-1 trans-infection. iMDDCs were treated with
ciglitazone or TO-901317 for 48 hours, extensively washed, and
then incubated for four hours with either a single-round
replication-competent HIV-1 reporter virus packaged with an
R5-tropic envelope or with wild-type HIV-1. Following incubation
with the virus, MDDCs were washed extensively to remove
unbound virus and then cultured directly with autologous T cells
or in the upper well of a Transwell insert separated from the T
cells by a 0.4 mm membrane. Although HIV-1 replicated very
poorly in immature MDDCs (Figure 3), we found that DCs were
able to mediate T cell infection when directly cultured with the T
cells or when separated from them by the Transwell insert
(Figure 3), suggesting that a portion of the MDDC-mediated trans-
infection is mediated by either exosome-associated HIV-1 [56] or
virus shed from the surface of MDDCs [57].
Most importantly, we found that PPARc and LXR ligands
inhibited trans-infection up to 5-fold underscoring their potential to
limit HIV-1 transmission (Figure 3). NR signaling inhibits trans-
infection of T cells by both single-round replication competent
virus (Figure 3) and wild-type replication competent virus
(Figure 4A), suggesting that the majority of virus transferred to
T cells is due to virus captured by the DC and not due to newly
synthesized virus. Because mature DCs capture and transfer HIV-
1 to T cells with higher efficiency than immature DCs [23,24,25],
we next determined whether PPARc or LXR ligands could inhibit
trans-infection mediated by LPS- or PAM3CSK4-matured
MDDCs. PPARc and LXR signaling repressed trans-infection of
autologous primary T cells mediated by both immature, LPS-
matured MDDCs (Figure 4A), and PAM3CSK4-matured
MDDCs (Figure 4B), suggesting that the repression is independent
of MDDC maturation. To confirm NR-dependent maturation-
independent repression of DC-mediated HIV-1 trans-infection, we
matured MDDCs with LPS for two days prior to treatment with
NR ligands and then assayed for HIV-1 transfer. As seen in
figure 4C, the ability of mature MDDCs to transfer virus was
impaired when treated with PPARc and LXR ligands. In addition,
we found that PPARc and LXR ligand treatment of MDDCs
prevented trans-infection over a wide range of input virus
(Figure 4D). Of note, NR-ligand treatment inhibited immature
and mature MDDC-mediated trans-infection of both R5- and X4-
tropic envelope glycoprotein-pseudotyped single-round replication
competent reporter viruses and replication-competent R5- and
X4- tropic wild-type HIV-1 (data not shown). Together these data
suggest that, unlike PPARc- and LXR-mediated inhibition of
migration, the inhibition of trans-infection is independent of the
maturation state of the DC. Importantly, MDDC-mediated trans-
infection is also inhibited by rosiglitazone (Figure 4E), a PPARc
agonist that is currently licensed for the systemic treatment of type
II diabetes.
PPARc and LXR ligands inhibit trans-infection at least in
part by blocking HIV-1 capture by MDDCs
Next, we wanted to examine the mechanism accounting for the
inhibition of trans-infection. We began by examining the effects of
PPARc or LXR ligand treatment on HIV-1 binding to MDDCs.
Ciglitazone and TO-901317 treatment led to a 2 to 5-fold
decrease in the amount of HIV-1 associated with MDDCs as
measured by an ELISA for the HIV-1 p24 capsid protein
(Figure 5A). Another PPARc ligand, rosiglitazone, was also tested
and had a comparable effect on HIV-1 capture (Figure 5B).
Treatment with these NR ligands also inhibited the capture of
HIV-1 by DCs at 4uC, suggesting that NR ligand treatment
Figure 2. PPARc and LXR ligand treatment prevents MDDC
migration in response to CCL21. (A) Immature (left panel) or
mature (right panel) MDDCs were seeded in the upper chamber of a
Transwell insert and allowed to migrate in response to medium or a
CCL21 gradient in the lower chamber. Migration indexes were
determined after four hours. On average, approximately 14% of
immature MDDCs (0.346105 cells) and 40% of LPS-matured MDDCs
(1.086105 cells) migrated through the Transwell insert in response to
CCL21. (n = 3) * p,0.005, ** p,0.001 compared to CCL21-treated
controls (B) MDDCs were treated with LPS for 48 hours in the presence
or absence of 100 mM ciglitazone or 1 mM TO-901317 and analyzed for
CCR7 expression by flow cytometry. Shaded histogram, isotype control.
Black line, iMDDCs. Blue line, LPS-treated MDDCs. Red line, LPS and
nuclear receptor ligand-treated MDDCs.
doi:10.1371/journal.ppat.1000981.g002
Figure 3. MDDCs are poorly infected with HIV-1 but can
mediate trans-infection of T cells. iMDDCs were treated for
48 hours with 100 mM ciglitazone or 1 mM TO-901317, washed
extensively, and then incubated with a single round replication-
competent HIV-1 reporter virus encoding luciferase and pseudotyped
with R5-tropic envelope glycoproteins. After four hours, unbound virus
was removed by extensive washing and the MDDCs were incubated
directly with PM1 T cells or separated from the PM1 T cells by a
Transwell insert with a 0.4 mm membrane for 48 hours. The cells were
then harvested, lysed, and assayed for luciferase activity. (n = 4) DC,
MDDCs cultured in the absence of T cells. DC + T, MDDCs cultured
directly with T cells. TW, MDDCs separated from T cells by a Transwell
insert. * p,0.001.
doi:10.1371/journal.ppat.1000981.g003
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Figure 4. NR ligand treatment prevents HIV-1 trans-infection. (A) Immature (left panel) and LPS-matured (right panel) MDDCs were treated for
48 hours with 100 mM ciglitazone or 1 mM TO-901317 (NR ligands were added one hour prior to TLR ligand addition), incubated with replication
competent HIV-1ADA, washed, and cultured directly with autologous T cells (DC + T) or separated from the T cells by a Transwell insert (TW) for a
period of 48 hours. Virus transfer and replication was measured by p24gag ELISA. DC + T, MDDCs cultured directly with T cells. TW, MDDCs separated
from T cells by a Transwell insert. Mean transfer/replication values: 9.18 ng p24gag for untreated iMDDCs cultured directly with T cells; and 85.5 ng
p24gag for untreated mMDDCs cultured directly with T cells. (n = 5) * (B) Immature (left panel) and PAM3CSK4-matured (right panel) MDDCs were
treated for 48 hours with 100 mM ciglitazone or 1 mM TO-901317, washed extensively, and then incubated with HIV-1ADA. After four hours, unbound
virus was removed by extensive washing and the MDDCs were incubated directly with autologous primary T for 48 hours. The cells were then
harvested, lysed, and assayed for virus transfer by p24gag ELISA. (n = 3) (C) MDDCs were treated with LPS and either 100 mM ciglitazone or 1 mM TO-
901317 for 48 hours (NR R TLR) or with LPS for 48 hours prior to treatment with NR ligands for an additional 48 hours (TLR R NR). MDDCs were
incubated with HIV-1ADA, washed, and cultured directly with autologous T cells. Virus transfer was measured by p24
gag ELISA. (n = 3) (D) Immature
(left panel) and LPS-matured (right panel) MDDCs were treated for 48 hours with 100 mM ciglitazone or 1 mM TO-901317 and incubated with
increasing amounts of HIV-1ADA, washed extensively, and then cultured with autologous T cells. Virus transfer was measured by p24
gag ELISA. (n = 3)
PPARc and LXR Inhibit DC-Mediated HIV-1 trans-Infection
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prevents DC binding of HIV-1 (Figure S2). In addition, we found
that PPARc and LXR ligand treatment of MDDCs prevented
capture over a wide range of input virus (Figure 5C). Although NR
signaling can repress inflammatory gene expression by a trans-
repression mechanism [30,31,32,33,34,36,37,38,52], it likely
decreases HIV-1 capture through a different mechanism. MDDCs
(E) Immature (left panel) and LPS-matured (right panel) MDDCs were treated for 48 hours with 1 mM rosiglitazone (hatched bars), incubated with HIV-
1ADA, washed, and cultured directly with autologous T cells. Virus transfer was measured by p24
gag ELISA. (n = 3) * p,0.001, ** p,0.005 compared to
untreated controls.
doi:10.1371/journal.ppat.1000981.g004
Figure 5. NR ligand treatment prevents HIV-1 trans-infection by blocking the capture of HIV-1 particles by MDDCs. (A) Immature (left
panel) and mature (right panel) MDDCs were treated with increasing concentrations of ciglitazone or TO-901317 for 48 hours. The MDDCs were then
incubated with 5 ng p24gag equivalent of HIV-1ADA and virus capture was measured by p24
gag ELISA. Mean capture values: 622.93 pg p24gag for
untreated iMDDCs; and 1.80 ng p24gag for untreatedmMDDCs. (n = 4) (B) Immature (left panel) andmature (right panel) MDDCs were treated with 1 mM
rosiglitazone (hatched bars) for 48 hours and analyzed as in (A). (n = 3) (C) Immature (left panel) and LPS-matured (right panel) MDDCs were treated for
48 hours with 100 mM ciglitazone or 1 mM TO-901317 and incubated with increasing amounts of HIV-1ADA, washed extensively, and lysed. Virus capture
was measured by p24gag ELISA. (n = 3) (D) iMDDCs were treated with 100 mM ciglitazone or 1 mM TO-901317 for various times, incubated with HIV-1ADA,
and assayed for virus capture by p24gag ELISA. (n = 3) (E) Immature MDDCs were treated with ciglitazone (100 mM) or TO-901317 (1 mM) for 48 hours,
incubated with HIV-1ADA for four hours at 37uC, and then washed to remove unbound virus. Some cells were incubated with virus at 4uC (as indicated).
The cells were then treated with 0.5% trypsin for 5 minutes at 37uC to degrade surface-bound virus particles, washed twice in culture medium, and lysed
as above. Virus capture was measured by p24gag ELISA. (n= 3) (F) iMDDCs were treated with either 100 mM ciglitazone or 1 mM TO-901317 for 48 hours
and cell-surface expression of CD4, CCR5, and DC-SIGN was measured by flow cytometry. Shaded histogram, isotype control. Blue line, iMDDCs. Red line,
nuclear receptor ligand-treated iMDDCs. * p,0.001 compared to untreated controls, ND, not detected.
doi:10.1371/journal.ppat.1000981.g005
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must be treated with PPARc and LXR ligands for at least
12 hours in order to observe inhibition of virus capture
(Figure 5D), suggesting that changes in cellular gene expression
are required for the observed effect. Though the amount of virus
captured by MDDCs upon NR ligand treatment was reduced, the
relative amount of virus particles internalized was similar
(Figure 5E) suggesting that reduced ability of MDDCs to capture
HIV-1 particles upon NR ligand treatment was not due to gross
reduction in cellular endocytic function. To confirm that NR
ligand treatment does not alter the ability of MDDCs to
internalize particles, we examined their effects on the ability of
MDDCs to macropinocytose FITC-labeled dextran. NR ligand
treatment had no effect on FITC-dextran internalization by
immature or mature MDDCs (Figure S3 and data not shown).
NR ligand treatment does not alter the expression of HIV-
1 attachment factors
Our data suggest that changes in cellular gene expression are
necessary for the observed decrease in HIV-1 capture by MDDCs.
We therefore considered the possibility that PPARc and LXR
ligand treatment altered the expression of known HIV-1
attachment factors expressed on the surface of immature MDDCs.
However, we found that NR ligand treatment did not alter the
expression of CD4, CCR5, or DC-SIGN (Figure 5F), which have
been implicated in DC capture of HIV-1 [5,58]. Despite these
findings, we cannot rule out whether NR signaling alters the
expression of other factors implicated in HIV-1 attachment such
as other C-type lectins [59,60,61,62], heparan sulfate proteogly-
cans [63,64,65], or GSLs [66,67,68,69,70].
NR ligand treatment prevents HIV-1 capture and transfer
by myeloid DCs
Although MDDCs are a faithful representation of myeloid or
conventional DCs (mDCs) with respect to their interactions with
HIV-1 [25], we decided to utilize mDCs freshly isolated from the
peripheral blood of healthy volunteers. We found that PPARc and
LXR signaling inhibited the ability of immature and LPS-matured
mDCs to capture HIV-1ADA and transfer it to autologous T cells
(Figure 6) in a manner consistent with results obtained using
MDDCs.
PPARc and LXR signaling does not prevent virological
synapse formation
Because direct DC-T cell contact is required for efficient virus
transfer [24,57] (and Figure 3), we wanted to determine whether
NR ligand treatment interfered with the ability of MDDCs to form
conjugates with T cells. Using a FACS-based conjugate formation
assay [71], we determined that NR ligand-treated MDDCs were
able to form conjugates with primary autologous T cells in a
manner similar to untreated MDDCs (Figure 7A). Because NR
ligand treatment did not alter the ability of DCs to form conjugates
with T cells, we next wanted to examine whether such treatment
prevented the formation of functional virological synapses between
DCs and T cells. Confocal microscopy data suggest that PPARc
and LXR ligand-treated DCs are capable of forming virological
synapses, as indicated by co-localization of virus and the
tetraspanin CD81 at the site of DC-T cell contact (Figure 7B).
However, number of virus particles localized at the virological
synapse is decreased in NR ligand-treated cells. Taken together,
Figure 6. PPARc and LXR ligand treatment inhibit myeloid DC-mediated HIV-1 capture and trans-infection. (A) Immature (left panel)
and mature (right panel) mDCs were treated with 100 mM ciglitazone or 1 mM TO-901317 for 48 hours. The mDCs were then incubated with HIV-1ADA
and virus capture was measured by p24gag ELISA. (n = 4) (B) Immature (left panel) and LPS-matured (right panel) mDCs were treated for 48 hours with
100 mM ciglitazone or 1 mM TO-901317, incubated with HIV-1ADA, washed, and cultured directly with autologous T cells. Virus transfer was measured
by p24gag ELISA. (n = 4) * p,0.001 compared to untreated controls.
doi:10.1371/journal.ppat.1000981.g006
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our data suggest that NR signaling impairs the ability of MDDCs
to transfer virus to T cells by inhibiting the capture of HIV-1 by
MDDCs.
PPARc and LXR ligands inhibit HIV-1 capture by MDDCs
in an envelope glycoprotein-independent manner
Recent studies have demonstrated that DCs can bind to
infectious HIV-1 and envelope-deficient virus-like particles
(VLPs) in a GSL-dependent, viral envelope glycoprotein-inde-
pendent manner [72,73]. We therefore wanted to assess whether
triggering PPARc and LXR signaling could alter the ability of
MDDCs to bind virus independently of the envelope glycoprotein
gp120. We found that PPARc and LXR ligand treatment led to a
2 to 5-fold decrease in the amount of envelope glycoprotein
(Env)-deficient HIV-1 particles captured by both immature and
mature MDDCs (Figure 8A), suggesting that GSL-based virus-
DC interactions may be targeted by NR signaling. To
demonstrate that this interaction is truly envelope glycoprotein-
independent, we also examined the effects of PPARc and LXR
signaling on the ability of DCs to capture HIV-1 particles
pseudotyped with the glycoproteins of vesicular stomatitis virus
Figure 7. PPARc and LXR ligand treatment do not prevent DC-T cell conjugate or virological synapse formation. (A) Primary
autologous CD4+ T cells were labeled with the cytoplasmic dye CMTMR for 30 minutes at 37uC, washed three times with PBS to remove excess dye,
and incubated overnight at 37uC. Following labeling, 56105 T cells were incubated with 2.56105 unlabeled iMDDCs for four hours at 37uC. The
conjugates were then fixed in 2% paraformaldehyde and conjugate formation was assessed by flow cytometry with gating on the MDDC population.
Shaded histogram, unlabeled MDDCs without T cells. Blue line, untreated MDDCs with T cells. Red line, nuclear receptor ligand-treated MDDCs with T
cells. (B) Primary autologous CD4+ T cells were labeled with the cytoplasmic dye CMCA (CellTracker Blue, Molecular Probes) for 30 minutes at 37uC,
washed three times with PBS to remove excess dye, and incubated overnight at 37uC. 2.56105 unlabeled LPS-matured MDDCs were incubated with
100 ng HIV-1NL4-3 virions packaged with Vpr-EGFP for four hours at 37uC, washed four times with PBS, and incubated with 5610
5 CMCA-labeled
autologous T cells for four additional hours. The cells were fixed in 1% paraformaldehyde, stained with anti-CD81-PE, and analyzed by deconvolution
microscopy.
doi:10.1371/journal.ppat.1000981.g007
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(VSV), Ebola virus (EboV), and Marburg virus (MarV). As shown
in figure 8B, treatment with PPARc and LXR ligands inhibited
the ability of DCs to capture EboV or MarV glycoprotein-
pseudotyped HIV-1 particles, whereas the treatment had no
effect on the ability of DCs to capture VSV-G-pseudotyped
particles. Since, like HIV-1, both EboV and MarV glycoproteins
are known to require cholesterol for infection [74,75], whereas
VSV-G does not [43,75,76], this suggested that PPARc and LXR
might be exerting their effects through the regulation of cellular
cholesterol.
PPARc and LXR ligand inhibits HIV-1 capture by MDDCs
in a cholesterol-dependent manner
Previous studies have shown that DC capture of HIV-1 is
dependent upon the cholesterol content of the cell membrane [51].
Since both PPARc and LXR are known to modulate genes
involved in cholesterol metabolism and transport [29,39,40,77],
we were interested in determining whether ciglitazone or TO-
901317 affected the cholesterol content of MDDCs. Treatment
with PPARc and LXR ligands increased cholesterol efflux from
immature MDDCs approximately 2 to 3-fold (Figure 9A) and led
to a concomitant 2-fold decrease in the amount of cholesterol in
immature MDDCs (Figure 9B). We next wanted to see if
cholesterol depletion resulting from PPARc and LXR ligand
treatment was responsible for the decreased ability of MDDCs to
capture and transfer HIV-1. In order to do this, we replenished
membrane cholesterol in PPARc and LXR ligand-treated
MDDCs using cholesterol-saturated methyl-b-cyclodextrin and
assayed for HIV-1 capture and transfer to T cells. Cholesterol
repletion of NR ligand-treated MDDCs with cholesterol-saturated
methyl-b-cyclodextrin restored cholesterol content (Figure 9B)
and, importantly, fully restored the ability of both immature and
mature MDDCs to capture HIV-1 (Figure 9C) and transfer it to
CD4+ T cells (Figure 9D).
PPARc and LXR signaling upregulate expression of ATP-
binding cassette protein A1 (ABCA1) that facilitates the apoA1-
dependent efflux of cholesterol from cells [39,41,77]. We therefore
examined whether treatment of DCs with ciglitazone or TO-
901317 affected ABCA1 expression. We found by western blot
analysis that both NR ligands increased ABCA1 expression
(Figure 9E). Importantly, targeted knockdown of ABCA1 using
shRNA abrogated the effect of PPARc and LXR ligand treatment
on cholesterol efflux (data not shown), HIV-1 capture by DCs
(Figure 9F), and HIV-1 transfer to T cells (Figure 9G). These
findings suggest that ligand-activated PPARc and LXR mediate
their effects through the depletion of cholesterol from the DC
plasma membrane via the up-regulation of the ABCA1 cholesterol
transport protein. It will be interesting to determine whether HIV-
1 particles interact directly with cholesterol in the plasma
membrane of DCs or with factors that localize to cholesterol-
rich lipid rafts.
Discussion
Sexual transmission of HIV-1 is enhanced by inflammatory and
ulcerative co-infections with STI pathogens that cause diseases such
as genital herpes, gonorrhea, syphilis, Chlamydia, bacterial
vaginosis, and fungal infections [78,79,80,81,82,83]. This enhanced
susceptibility to infection may be due to a number of factors,
including disruption of epithelial integrity [6,11,14,84,85,86,87],
recruitment of HIV-1 target cells such as Langerhans cells, DCs,
macrophages, and T lymphocytes to sites of inflammation [8], and
Figure 8. PPARc and LXR ligand treatment prevents envelope glycoprotein-independent capture of virus by MDDCs. (A) Immature
(left panel) and mature (right panel) MDDCs were treated with 100 mM ciglitazone or 1 mM TO-901317 and incubated with a single round replication-
competent HIV-1 reporter virus encoding luciferase that was either pseudotyped with R5-tropic envelope glycoproteins (R5) or that lacked envelope
glycoproteins (DEnv). Virus capture was measured by p24gag ELISA. (n = 3) (B) Immature MDDCs were treated with100 mM ciglitazone or 1 mM TO-
901317 and incubated with a single round replication-competent HIV-1 reporter virus encoding luciferase that was packaged with envelope
glycoproteins from VSV (VSV-G), Ebola virus Zaire (EboV-Z), Ebola virus Sudan (EboV-S), or Marburg virus (MarV). Virus capture was measured by
p24gag ELISA. Mean capture values for untreated iMDDCs: 1.13 ng VSV-G-pseudotyped HIV-1; 251.83 pg EBOV-Z-pseudotyped HIV-1; 324.10 pg
EBOV-S-pseudotyped HIV-1; and 415.07 pg MARV-pseudotyped HIV-1. (n = 3) * p,0.001 compared to untreated controls.
doi:10.1371/journal.ppat.1000981.g008
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activation of HIV-1 expression by pro-inflammatory cytokines or
microbial components [21,22,88,89,90,91,92]. It is likely that STI
pathogens enhance these latter two processes, at least in part,
through engagement of the TLR family of innate immune
receptors. Clearly, prophylactic methods that inhibit infection of
the genital or rectal mucosa would significantly limit the global
spread of HIV. To this end, considerable efforts have been directed
toward the development of microbicides that interfere with virus
integrity or with key steps in virus replication. However, to date,
little attention has been paid to targeting cellular pathways involved
in active suppression of inflammation and its effects on mucosal
HIV-1 infection and virus dissemination. With this in mind, we
have focused our efforts on the nuclear receptor family of tran-
scription factors that have recently been shown to be potent inhib-
itors of TLR-induced inflammation [30,31,32,33,34,36,37,38].
Here, we demonstrate that PPARc and LXR signaling inhibit
several aspects of DC biology that are important for HIV-1 mucosal
transmission. These include TLR-induced pro-inflammatory cyto-
kine expression, DC migration in response to the chemokine,
CCL21, and, importantly, DC-mediated capture of infectious virus
particles and trans-infection of CD4+ T cells. Our findings highlight
the therapeutic potential of PPARc and LXR ligands as topical
treatments that could be used in conjunction with conventional
microbicides to limit mucosal transmission of HIV-1.
DC-mediated trans-infection of T cells is thought to play a
critical role in the mucosal transmission of HIV-1. Studies suggest
that DCs can mediate trans-infection either by internalizing
infectious virions into a protected tetraspanin-rich intracellular
compartment, or deep membrane invaginations contiguous with
the cell surface, and releasing them for the subsequent infection of
T cells [5,56,73,93,94,95] or by retaining virions at the cell surface
and transferring them to T cells [57,95]. Regardless of the
mechanism, maturation of DCs with ligands for TLRs such as
TLR4 and TLR2/TLR1 increases DC-mediated HIV-1 capture
and trans-infection of T cells. DC maturation also contributes to
HIV-1 mucosal transmission in a number of other ways. Mature
DCs create a pro-inflammatory environment that favors virus
replication [20,88,96,97,98] and leads to disruption of the mucosal
integrity [83,99]. Mature DCs may also contribute to virus
dissemination by virtue of their enhanced ability to traffic to
regional lymph nodes in response to chemokine gradients and,
once there, transfer virus to resident CD4+ T cells. Here we show
that PPARc or LXR ligand treatment can prevent DC maturation
as measured by the expression of cell surface markers such as
Figure 9. PPARc and LXR signaling inhibit HIV-1 capture and transfer by MDDCs via ABCA1-dependent cholesterol efflux. (A)
iMDDCs were treated for 48 hours with 100 mM ciglitazone or 1 mM TO-901317 and cholesterol efflux into the culture supernatant was measured.
(n = 3) (B) iMDDCs were treated for 48 hours with 100 mM ciglitazone and 1 mM TO-901317. The cells were then lysed and cholesterol content of the
cell lysates was measured. (n = 3) (C-D) Immature (left panel) and mature (right panel) MDDCs were treated with 100 mM ciglitazone or 1 mM TO-
901317 for 48 hours. NR ligand-treated cells were then incubated with 300 mM cholesterol in the form of cholesterol-saturated methyl-b-cyclodextrin.
Following cholesterol repletion, the cells were used in capture (C) and transfer assays (D) as described in the legend of figure 2. (n = 3) (E) iMDDCs
transfected with either control shRNA or shRNA directed against ABCA1 were treated for 48 hours with 100 mM ciglitazone or 1 mM TO-901317. Levels
of ABCA1 and b-actin were measured by immunoblot using an anti-ABCA1 and anti-b-actin antibodies, respectively. (n = 3) (F) iMDDCs transfected
with either control shRNA or shRNA directed against ABCA1 were treated for 24 hours with 100 mM ciglitazone (gray bars) or 1 mM TO-901317 (black
bars). The MDDCs were then incubated with HIV-1ADA and virus capture was measured by p24
gag ELISA. (n = 3) (G) iMDDCs transfected with either
control shRNA or shRNA directed against ABCA1 were treated for 24 hours with 100 mM ciglitazone (gray bars) or 1 mM TO-901317 (black bars). The
MDDCs were then incubated with HIV-1ADA, washed extensively, and then incubated with autologous T cells. Virus transfer was measured by p24
gag
ELISA. Transfer assays with shRNA-treated DCs were performed using cells from two independent donors. * p,0.001 compared to untreated controls.
doi:10.1371/journal.ppat.1000981.g009
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HLA-DR, CD80, and CD86 (Figure 1A). Importantly, treatment
with PPARc or LXR ligands also potently inhibit expression of
maturation-associated pro-inflammatory cytokines (Figure 1B),
such as TNF-a and IL-6 and the pro-inflammatory chemokine,
IL-8, that have been shown to augment HIV-1 replication in
infected cells and to increase HIV-1 transmission to T cells
[21,22,91,100]. Moreover, we demonstrate that PPARc and LXR
signaling can interfere with the migration of DCs in response to a
CCL21 chemokine gradient (Figure 2A). This appears to be due to
the effects of PPARc and LXR signaling on the expression of
CCR7 (Figure 2B), one of the receptors for CCL21. CCR7 is up-
regulated upon DC maturation and has been shown to be
important for the migration of DCs from the mucosa to regional
lymph nodes in vivo [54]. By preventing DC migration in response
to CCL21, PPARc and LXR ligands may help to block the
dissemination of DC-associated virus from mucosal sites of
infection to regional lymph nodes.
Recent studies demonstrated that activation/maturation of
DCs through TLR4 or TLR2/TLR1 enhances HIV-1 transmis-
sion to target cells via increased HIV-1 capture [23,24,25,92] and
Figure 4 and 5). Here, we demonstrate that activating PPARc or
LXR signaling pathways in DCs decreases the ability of both
immature and TLR-matured DCs to capture and transfer HIV-1
to T cells (Figure 3, 4A and 5A). Furthermore, NR signaling can
inhibit HIV-1 transfer by previously matured DCs (Figure 4C)
These results suggest that PPARc and LXR signaling alter other
pathways involved with HIV-1 trans-infection that are indepen-
dent of the maturation state of the DC (Figure 4C), however we
cannot rule out the possibility that the prevention of DC
maturation may contribute to the NR-mediated decrease in
HIV-1 capture and transfer. Many studies have demonstrated a
role for PPARc and LXR signaling in cholesterol metabolism and
transport [29,39,40]. For example, both signaling pathways
stimulate the expression of ABCA1 and ABCG1, which have
been implicated in apolipoprotein A1 (ApoA1)- and high density
lipoprotein (HDL)-mediated cholesterol efflux, respectively [39].
Given the importance of cholesterol for a number of aspects
of HIV-1 biology, including virus binding and infection
[42,43,44,45,47,48,49,50,51,76], we hypothesized that PPARc
and LXR signaling was altering the cholesterol content of DC
membranes, thereby rendering them incapable of efficiently
binding HIV-1 particles. Previous studies have demonstrated that
treatment with cholesterol depleting drugs, such as methyl-b-
cyclodextrin, or with cholesterol synthesis inhibitors, such as
HMGCoA-reductase inhibitors (statins), alters the ability of cells,
including DCs, to bind HIV-1 and renders them refractory to
HIV-1 infection [42,43,45,49,50,51,101]. Here, we show that
cholesterol repletion of PPARc and LXR ligand-treated DCs
reverses the effects of the NR ligands on virus capture and
transfer (Figure 9C and 9D), confirming that PPARc and LXR
are mediating their effects through membrane cholesterol. In
addition, targeted shRNA knock-down of ABCA1 abrogates the
effects of PPARc and LXR signaling on HIV-1 capture and
transfer (Figure9F and 9G). A recent study suggests that LXR-
dependent cholesterol efflux in macrophages is mediated entirely
through ABCA1, with little to no contribution from ABCG1
[102]. We cannot, however, formally exclude a contribution from
ABCG1-dependent cholesterol efflux to the effects we report
here. Our data show that PPARc and LXR signaling decrease
cellular cholesterol content, which may in turn deplete cholesterol
from membrane lipid rafts. It will be interesting to determine
whether treatment of DCs with PPARc and LXR ligands disrupts
lipid rafts and whether this accounts for the decreased ability or
NR-treated DCs to capture and transfer HIV-1.
We found that PPARc and LXR ligand treatments do not alter
the levels of a number of known virus attachment factors expressed
on DCs including CD4, CCR5, and DC-SIGN (Figure 5F).
Moreover, PPARc and LXR signaling prevents the capture of
Env-deficient HIV-1 virus like particles (Figure 8A), suggesting
that virus envelope glycoprotein/receptor interactions are not
involved in the observed effect. That the effects of PPARc and
LXR signaling on HIV-1 capture are virus envelope glycoprotein-
independent is supported by our finding that treatment of DCs
with ciglitazone or TO-901317 prevents the capture of viral
particles pseudotyped with the envelope glycoproteins of Ebola
virus and Marburg virus (Figure 8B). Interestingly, these two
viruses are known to require cholesterol for infection [74,75]. In
contrast, treatment with the NR ligands had no effect on the
ability of DCs to capture virus particles pseudotyped with the
envelope glycoprotein of VSV. Previous studies have demonstrat-
ed that VSV-G-pseudotyped HIV-1 particles are efficiently
captured by cells depleted of cholesterol using methyl-b-cyclodex-
trin [43,75,76]. These data further support the hypothesis that
PPARc and LXR signaling alter the membrane cholesterol
content of DCs, rendering them incapable of efficiently capturing
HIV-1 particles.
Although NR ligand treatment limits the expression of immune-
activating cytokines and co-stimulatory molecules that are up-
regulated as DCs mature, we found that it does not alter the
ability of DCs to form conjugates with T cells. The number of DC-
T cell conjugates formed with PPARc and LXR ligand-treated
DCs was comparable to that of control untreated DCs (Figure 7A).
It will be interesting to determine whether these conjugates
represent functional immunological synapses between DCs and T
cells. It is worth noting that DC-to-T cell transfer of HIV-1 most
likely occurs through the formation of virological synapses
[103,104,105,106,107,108]. We found that NR ligand treatment
does not prevent the formation of virological synapses between
DCs and T cells as assessed by confocal microscopy, although
ligand treatment does seem to decrease the amount of virus
concentrated at the virological synapse (Figure 7B).
Beyond demonstrating the ability of PPARc and LXR signaling
pathways to prevent DC capture and transfer of virus, our results
provide support for a number of observations regarding the
interactions between DCs and HIV-1. First, we demonstrate that
immature DCs can transfer single round replication competent
virus to T cells through a Transwell insert that prevents direct
contact between the two cell types (Figure 3). Although direct cell-
cell contact is required for efficient virus transfer, our data suggest
that approximately 20% of infectious virus can be transferred by
immature DCs via exosomes or shedding from the cell surface. In
contrast, although mature DCs bind approximately 10-fold more
virus, less than 10% of transfer is mediated through cell-surface
bound viral particles (Figure 4A). Second, our data suggest that a
large percentage of virions captured by DCs is internalized or
otherwise protected from proteases (Figure 5E). Previous studies
have demonstrated that DCs internalize HIV-1, resulting in either
degradation of virus particles [56,65,109], establishment of
productive infection [110,111,112], or sequestration into protected
intracellular compartments [56,73,94,95]. Although PPARc and
LXR signaling alters the amount of virus captured by DCs, it does
not seem to alter the percentage of captured virus that is
internalized by DCs (Figure 5E). This is not surprising, since
PPARc and LXR ligand treatment does not alter the endocytic
capacity of DCs, as measured by the internalization of FITC-
dextran (Figure S2). Finally, our data confirm that DCs can bind
virus particles in a gp120-independent manner (Figure 8A).
Recent reports demonstrate that host cell-derived GSLs incorpo-
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rated into the budding virus particle play a critical role in
mediating HIV-1 capture by immature and mature DCs in a
gp120-independent manner [72,73]. Taken together with current
and previous findings that cholesterol depletion from DC
membranes prevents HIV-1 binding [51] (and Figure 9C), these
data argue for the presence of a yet-to-be-identified GSL-
recognizing attachment factor(s) within lipid raft-like membrane
microdomains at the surface of DCs whose function is compro-
mised upon NR ligand treatment.
NR signaling may have beneficial effects on the prevention of
HIV-1 transmission beyond the effects on pro-inflammatory
cytokine production, migration, and virus capture and transfer.
STIs, through engagement of TLRs, and STI/TLR-induced
inflammation, can directly activate HIV-1 replication in infected
cells. Our data suggest that both PPARc and LXR ligands repress
HIV-1 replication in DCs (Figure 3), although the levels of
replication in this cell type are quite low. This finding is consistent
with previous studies that have shown that PPARc ligands repress
HIV-1 expression in infected monocytes and macrophages
[113,114,115]. Recent findings from our laboratory suggest that
NR-mediated repression of HIV-1 replication is due to trans-
repression (T. Hanley and G. Viglianti, manuscript in preparation),
as is thought to be the case for NR-mediated repression of pro-
inflammatory cytokine production [30,31,32,33,34,35,36,37,38].
Although our data suggest that the majority of virus transferred to T
cells is due to virus captured by DCs, and not due to virus newly
synthesized in infected DCs, NR-mediated inhibition of HIV-1
replication may contribute to the inhibition of trans-infection that we
report here. By preventing HIV-1 replication, in addition to DC
migration, pro-inflammatory cytokine and chemokine production,
and trans-infection, PPARc and LXR ligands may block the
dissemination of DC-associated virus from the local site of infection
to regional lymph nodes.
In the absence of an effective vaccine for HIV-1, the
development of topical microbicides that block the early steps of
HIV-1 infection and transmission may represent the best option
for containing the spread of this global pandemic. To date, there
has been limited success with antiviral microbicides. In order to
ensure success with future microbicide development, a much
greater understanding of the mechanisms involved in the very
early stages of mucosal infection and transmission of HIV-1, and
the role of DCs in HIV-1 pathogenesis, in particular, are required.
Our results contribute to a better delineation of the mechanisms
underlying the HIV-1 trans-infection activity of DCs, while having
implications for the development of new anti-HIV microbicide
strategies. PPARc and LXR ligands are small lipophilic molecules
that readily diffuse across cell membranes and might be amenable
to topical formulations. Two PPARc agonists, rosiglitazone and
pioglitazone, are currently approved for the systemic treatment of
type II diabetes. A limitation of the present study is that we have
not yet examined the effects of NR signaling on HIV-1
transmission in the context of a complex tissue model or an
animal model. Despite this limitation, the anti-inflammatory and
anti-HIV-1 activities of PPARc and LXR provide a solid rationale
for considering them as drug targets that can act synergistically
with conventional anti-viral microbicides that target other aspects
of mucosal transmission including virion structure, virus binding/
entry, or reverse transcription.
Materials and Methods
Ethics statement
This research has been determined to be exempt by the
Institutional Review Board of the Boston University Medical
Center since it does not meet the definition of human subjects
research.
Cell isolation and culture
Primary human CD14+ monocytes were isolated from the
peripheral blood mononuclear cells (PBMCs) of healthy donors
using anti-CD14 magnetic beads (Miltenyi Biotec) per the
manufacturer’s instructions. CD14+ monocytes (1.56106 cells/
ml) were cultured in RPMI 1640 supplemented with 10% FBS,
100 U/ml penicillin, 100 mg/ml streptomycin, 0.29 mg/ml L-
glutamine, 1000 U/ml IL-4 (PeproTech), and 1400 U/ml GM-
CSF (PeproTech) for 6-8 days at the end of which the cells
acquired an immature dendritic cell phenotype as assessed by flow
cytometry (CD11c+, DC-SIGN+, HLA-DRlo, CD802, CD862).
Cells were given fresh medium supplemented with IL-4 and GM-
CSF every 2 days. Mature dendritic cells were obtained following
48 hour exposure to 100 ng/ml ultra-pure E. coli K12 LPS or
100 ng/ml PAM3CSK4. Primary human myeloid DCs (mDCs)
and plasmacytoid DCs (pDCs) were isolated from monocyte- and
B cell-depleted PBMCs using anti-CD11c and anti-BDCA4
magnetic beads (Miltenyi Biotec) per the manufacturer’s instruc-
tions. mDCs were cultured in RPMI 1640 with 10% FBS, 100 U/
ml penicillin, 100 mg/ml streptomycin, 0.29 mg/ml L-glutamine,
1000 U/ml IL-4, and 1400 U/ml GM-CSF. pDCs were cultured
in RPMI 1640 supplemented with 10% FBS, 100 U/ml penicillin,
100 mg/ml streptomycin, 0.29 mg/ml L-glutamine, and 10 ng/ml
IL-3 (PeproTech). Primary human CD4+ T cells were isolated
from CD14-depleted peripheral blood mononuclear cells using
anti-CD4 magnetic beads (Miltenyi Biotec) per the manufacturer’s
instructions. CD4+ T cells (26106 cells/ml) were cultured in
RPMI 1640 supplemented with 10% FBS, 100 U/ml penicillin,
100 mg/ml streptomycin, 0.29 mg/ml L-glutamine, 50 U/ml IL-2
(R&D Systems), and 5 mg/ml PHA-P (Sigma) for 6-8 days at the
end of which the cells acquired a memory T cell phenotype as
assessed by flow cytometry (CD3+, CD4+, CD45RO+, CD45RA–).
293T cells were cultured in DMEM supplemented with 10% FBS,
100 U/ml penicillin, 100 mg/ml streptomycin, and 0.29 mg/ml
L-glutamine. MAGI-CCR5 cells were cultured in DMEM
supplemented with 10% FBS, 100 U/ml penicillin, 100 mg/ml
streptomycin, 0.29 mg/ml L-glutamine, 500 mg/ml G418, 1 mg/
ml puromycin, and 0.1 mg/ml hygromycin B. PM1 cells were
cultured in RPMI 1640 supplemented with 10% FBS, 100 U/ml
penicillin, 100 mg/ml streptomycin, and 0.29 mg/ml L-glutamine.
Nuclear receptor and Toll-like receptor ligands
The LXR ligand TO-901317 was purchased from Calbiochem.
The PPARc ligands ciglitazone and rosiglitazone were purchased
from Cayman Chemicals. The ligands were reconstituted in
DMSO. The TLR2 ligand PAM3CSK4, the TLR4 ligand E. coli
K12 LPS, the TLR7 ligand CLO97, and the TLR9 ligand CpG
ODN 2006 were purchased from Invivogen. Unless otherwise
noted, DCs were treated with PPARc and LXR ligands for 24–
48 hours, beginning one hour prior to treatment with TLR
ligands.
Virus production
Replication competent R5-tropic HIV-1ADA and X4-tropic
HIV-1NL4-3 were generated by infection of PM1 cells. Single-
round replication-competent HIV-1-based reporter viruses were
generated by packaging a luciferase expressing reporter virus,
BruDEnvLuc2, with the envelope glycoproteins from CCR5-tropic
HIV-1(Ada-M), CXCR4-tropic HIV-1(HXB2), VSV (VSV-G),
Ebola virus Zaire (EboV-Z), Ebola virus Sudan (EboV-S), or
Marburg virus (MarV). EGFP-labeled virus particles were
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generated by co-transfection of the pro-viral clone HIV-1NL4-3
with an expression vector encoding a Vpr-EGFP fusion protein.
Virus stocks were generated by transfecting HEK293T cells using
the calcium phosphate method. All viruses were titered on MAGI-
CCR5 cells and p24gag content was determined by ELISA.
Transfer assays
To assess DC-mediated transfer of HIV-1 to T cells, DCs were
incubated with Ada-M- or HXB2-pseudotyped HIV-luciferase
reporter virus at an MOI = 0.1 (37.8–40.4 ng p24gag) for four
hours at 37uC. Cells were washed five times with PBS to remove
unbound virus, seeded in 96-well plates (2.56105 cells/well), and
then cultured with either PM1 T cells (56105 cells/well) or
autologous primary CD4+ T cells (56105 cells/well) for 48 hours.
In some instances, the DCs were seeded in 24-well plates separated
from the T cells by a Transwell insert (Corning) with a 0.4 mm
pore size. As controls, virus-exposed DCs and virus-exposed T
cells were cultured alone for 48 hours. After 48 hours, the cells
were harvested, washed two times with PBS, and lysed in PBS/
0.02% Triton X-100. Protein levels in cell lysates were determined
using a modified Lowry protein assay (BioRad) and luciferase
activity was measured using luciferase reagent (Promega) and a
MSII luminometer (Molecular Devices). In some experiments,
replication competent R5-tropic HIV-1ADA or X4-tropic HIV-
1NL4-3 (5 ng p24
gag) were used in place of packaged reporter virus
and transfer was measured by p24gag ELISA.
Capture assays
DCs (2.56105 cells/well) were incubated with replication
competent R5-tropic HIV-1ADA or X4-tropic HIV-1NL4-3 (5 ng
p24gag) for three to four hours at 37uC. Cells were washed four to
five times with PBS to remove unbound virus, and lysed in PBS/
10%FBS/0.5% Triton X-100. In some experiments, virus-exposed
DCs were incubated with 0.5% trypsin for 5 minutes at 37uC to
degrade surface-bound virus particles, washed twice in culture
medium, and then lysed as above. An ELISA was used to
determine the amount of p24gag protein associated with the cells.
In some experiments, Ada-M-, HXB2-, VSV-G, EboV-, or MarV-
packaged HIV-luciferase reporter virus (5 ng p24gag) or an equal
amount of reporter virus lacking envelope glycoproteins (DEnv)
was used.
DC-T cell conjugate formation assays
Primary CD4+ T cells were labeled with the cytoplasmic dye
CMTMR (CellTracker Orange, Molecular Probes) for 30 minutes
at 37uC and then washed three times with PBS to remove excess
dye. Cells were then incubated for 16 hours at 37uC and washed
twice with PBS prior to use in conjugate formation assays.
Following labeling, 56105 T cells were incubated with 2.56105
unlabeled iMDDCs for four hours at 37uC in a total volume of
200 ml. The conjugates were then fixed by gently adding an equal
volume of 4% paraformaldehyde. Samples were run immediately
through a flow cytometer. Conjugate formation was assessed by
fluorescence associated with the MDDC population.
Virological synapse formation assays
Primary CD4+ T cells were labeled with the cytoplasmic dye
CMCA (CellTracker Blue, Molecular Probes) for 30 minutes at
37uC and then washed three times with PBS to remove excess dye.
T cells were then incubated for 16 hours at 37uC and washed
twice with PBS prior to use in virological synapse formation assays.
2.56105 unlabeled mMDDCs were incubated with 100 ng HIV-
1NL4-3 virions packaged with Vpr-EGFP for four hours at 37uC,
washed four times with PBS, and incubated with 56105 CMCA-
labeled autologous T cells for four additional hours. The cells were
fixed in 1% paraformaldehyde, stained with anti-CD81-PE (BD
Pharmingen). Z-stacks were captured on the Nikon deconvolution
wide-field Epifluorescence Scope at 1006. Using ImageJ software,
the images were deconvolved and the fluorescence was summed.
Cholesterol repletion assays
Cholesterol-saturated methyl-b-cyclodextrin was prepared as
previously described [116]. Briefly, cholesterol powder was added
to 240 mM methyl-b-cyclodextrin solution at 1.16 mg/ml,
agitated overnight, and filter sterilized using a 0.22-mm filter. To
replete cholesterol, MDDCs were incubated with cholesterol-
saturated methyl-b-cyclodextrin at a concentration of 300 mM
cholesterol for 30 minutes at 37uC and then washed five times with
PBS before being used in virus capture and transfer studies.
Transwell migration assays
MDDCs (2.56105 cells) were seeded above a Transwell insert
with a 5 mm pore size and allowed to migrate through the insert in
response to medium or CCL21 (PeproTech). Cells above and below
the Transwell insert were fixed in 2% paraformaldehyde and
counted in a hemocytometer to determine the relative migratory
capacity of theMDDCs.Migration index was calculated by dividing
the number of experimental cells that migrated in response to
CCL21 by the number of untreated cells that migrated in response
to media alone.
Cholesterol efflux assays
Cholesterol efflux into cell-free culture supernatants and
cholesterol content of lysed MDDCs were measured using the
AmplexRed cholesterol assay kit per the manufacturer’s instruc-
tions (Invitrogen).
shRNA knock-down of ABCA1
MDDCs were transfected with plasmids that encoded either a
mixture of three to five shRNAs directed against ABCA1 or
a mixture of control shRNAs (Santa Cruz Biotechnology) and a
puromycin-resistance gene using Oligofectamine (Invitrogen) per
the manufacturer’s instructions. Transfected cells were selected by
culture in the presence of puromycin for 48 hours and then used
for cholesterol efflux assays, used for HIV-1 capture assays, or
lysed for immunoblot analysis to measure ABCA1 expression.
Flow cytometry
MDDC phenotypes were assessed using antibodies against
HLA-DR, CD80, CD86, DC-SIGN, CD11c, CD4, CCR5,
CXCR4, and CCR7. Primary CD4+ T cell phenotypes were
assessed using antibodies to CD3, CD4, CD8, CD45RO,
CD45RA, CCR5, and CXCR4. Flow cytometric data was
acquired using a Becton-Dickenson FACScan II and data was
analyzed using FlowJo software.
Cytokine and chemokine release assays
MDDCs (2.56105 cells/well) or pDCs (16105 cells/well) were
treated with PAM3CSK4 (100 ng/ml), LPS (100 ng/ml), CLO97
(1 mg/ml), or CpG ODN 2006 (5 mM) for 24 hours in the
presence or absence of nuclear receptor ligands as described in the
legend to figure 1. Cell-free culture supernatants were collected
and analyzed for TNF-a (eBioscience), IL-6 (eBioscience), IL-8
(BioLegend), MIP-1a (PeproTech), and RANTES (PeproTech)
release by commercially-available ELISA following the manufac-
turer’s instructions.
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Cell viability assays
MDDC cell viability was assessed by trypan blue dye exclusion,
MTT cytotoxicity assay, and LDH release using a commercial kit
(Promega) per the manufacturer’s instructions.
Statistical analysis
Untreated control and ligand-treated experimental samples
were compared using a two-tailed t-test. Experiments were
performed in duplicate (mDCs and pDCs) or triplicate (MDDCs)
using cells from a minimum of three different donors as indicated
in the figure legends (n). Data are presented as the mean 6
standard deviation of pooled data from at least three donors.
Accession numbers
PPARc Swiss-Prot # P37231; LXRa Swiss-Prot # Q13133;
LXRb Swiss-Prot# P55055; CCR7 Swiss-Prot# P32248; CCL21
Swiss-Prot # O00585;TLR1 Swiss-Prot # Q15399; TLR2 Swiss-
Prot#O60603; TLR4 Swiss-Prot#O00206; TLR7 Swiss-Prot#
Q9NYK1; TLR9 Swiss-Prot # C3W5P5; ABCA1 Swiss-Prot #
O95477; ABCG1 Swiss-Prot # P45844.
Supporting Information
Figure S1 PPARc and LXR ligand treatment do not alter
MDDC viability. Immature MDDCs were treated for 48 hours
with 100 mM ciglitazone or 1 mM TO-901317. Cell viability was
assessed by the release of LDH into the cell culture supernatant.
(n = 3).
Found at: doi:10.1371/journal.ppat.1000981.s001 (0.09 MB TIF)
Figure S2 PPARc and LXR ligand treatment inhibit HIV-1
binding to MDDCs. Immature MDDCs were treated for 48 hours
with 100 mM ciglitazone or 1 mM TO-901317 and incubated with
HIV-1ADA for 3–4 hours at 4uC. Following incubation with virus,
cells were washed four times with ice cold PBS and then lysed.
Virus capture was measured by p24gag ELISA. (n = 3) * p,0.001
compared to untreated controls.
Found at: doi:10.1371/journal.ppat.1000981.s002 (0.05 MB
TIF)
Figure S3 PPARc and LXR ligand treatment do not prevent
MDDC uptake of FITC-dextran. Immature MDDCs treated with
100 mM ciglitazone (upper panel) or 1 mM TO-901317 (lower
panel) were incubated with FITC-dextran (100 mg/ml) for two
hours at 37uC and then washed extensively to remove unbound
FITC-dextran. The cells were then fixed in 2% paraformaldehyde
and uptake of FITC-dextran was assessed by flow cytometry.
Shaded histogram, MDDCs without FITC-dextran. Blue line,
untreated MDDCs. Red line, nuclear receptor ligand-treated
MDDCs.
Found at: doi:10.1371/journal.ppat.1000981.s003 (0.32 MB TIF)
Acknowledgments
The authors wish to thank Nuria Izquierdo-Useros for help with the DC-T
cell conjugate formation assay and Dr. Elke Muehlberger for providing the
EboV-Z, EboV-S, and MarV envelope glycoprotein expression vectors.
The authors would like to acknowledge Mike Kerber and the Boston
University Cellular Imaging Core for technical assistance. The authors also
wish to thank Drs. Andrew Henderson and Ann Marshak-Rothstein for
comments on the manuscript. The following reagents were obtained
through the AIDS Research and Reference Reagent Program, Division of
AIDS, NIAID, NIH: HIV-1ADA from Dr. Howard Gendelman; pHXB2-
env from Dr. Kathleen Page and Dr. Dan Littman; HIV IG from NABI
and National Heart Lung and Blood Institute (Dr. Luiz Barbosa); anti-
p24gag monoclonal antibody clone 183-H12-5C from Dr. Bruce Chesebro
and Kathy Wehrly; and MAGI-CCR5 cells from Dr. Julie Overbaugh.
Author Contributions
Conceived and designed the experiments: TMH SG GAV. Performed the
experiments: TMH WBP. Analyzed the data: TMH WBP SG GAV.
Wrote the paper: TMH SG GAV.
References
1. Shattock RJ, Moore JP (2003) Inhibiting sexual transmission of HIV-1
infection. Nat Rev Microbiol 1: 25–34.
2. Gouws E, White PJ, Stover J, Brown T (2006) Short term estimates of adult
HIV incidence by mode of transmission: Kenya and Thailand as examples. Sex
Transm Infect 82 Suppl 3: iii51–55.
3. Pope M, Haase AT (2003) Transmission, acute HIV-1 infection and the quest
for strategies to prevent infection. Nat Med 9: 847–852.
4. Miller CJ, Li Q, Abel K, Kim EY, Ma ZM, et al. (2005) Propagation and
dissemination of infection after vaginal transmission of simian immunodefi-
ciency virus. J Virol 79: 9217–9227.
5. Geijtenbeek TB, Kwon DS, Torensma R, van Vliet SJ, van Duijnhoven GC,
et al. (2000) DC-SIGN, a dendritic cell-specific HIV-1-binding protein that
enhances trans-infection of T cells. Cell 100: 587–597.
6. Hu J, Gardner MB, Miller CJ (2000) Simian immunodeficiency virus rapidly
penetrates the cervicovaginal mucosa after intravaginal inoculation and infects
intraepithelial dendritic cells. J Virol 74: 6087–6095.
7. Fong L, Mengozzi M, Abbey NW, Herndier BG, Engleman EG (2002)
Productive infection of plasmacytoid dendritic cells with human immunode-
ficiency virus type 1 is triggered by CD40 ligation. J Virol 76: 11033–11041.
8. Gupta P, Collins KB, Ratner D, Watkins S, Naus GJ, et al. (2002) Memory
CD4(+) T cells are the earliest detectable human immunodeficiency virus type
1 (HIV-1)-infected cells in the female genital mucosal tissue during HIV-1
transmission in an organ culture system. J Virol 76: 9868–9876.
9. Jameson B, Baribaud F, Pohlmann S, Ghavimi D, Mortari F, et al. (2002)
Expression of DC-SIGN by dendritic cells of intestinal and genital mucosae in
humans and rhesus macaques. J Virol 76: 1866–1875.
10. Pudney J, Quayle AJ, Anderson DJ (2005) Immunological microenvironments
in the human vagina and cervix: mediators of cellular immunity are
concentrated in the cervical transformation zone. Biol Reprod 73: 1253–1263.
11. Hladik F, Sakchalathorn P, Ballweber L, Lentz G, Fialkow M, et al. (2007)
Initial events in establishing vaginal entry and infection by human
immunodeficiency virus type-1. Immunity 26: 257–270.
12. Bomsel M (1997) Transcytosis of infectious human immunodeficiency virus
across a tight human epithelial cell line barrier. Nat Med 3: 42–47.
13. Bobardt MD, Chatterji U, Selvarajah S, Van der Schueren B, David G, et al.
(2007) Cell-free human immunodeficiency virus type 1 transcytosis through
primary genital epithelial cells. J Virol 81: 395–405.
14. Spira AI, Marx PA, Patterson BK, Mahoney J, Koup RA, et al. (1996) Cellular
targets of infection and route of viral dissemination after an intravaginal
inoculation of simian immunodeficiency virus into rhesus macaques. J Exp
Med 183: 215–225.
15. Hu Q, Frank I, Williams V, Santos JJ, Watts P, et al. (2004) Blockade of
attachment and fusion receptors inhibits HIV-1 infection of human cervical
tissue. J Exp Med 199: 1065–1075.
16. Banchereau J, Steinman RM (1998) Dendritic cells and the control of
immunity. Nature 392: 245–252.
17. Steinman RM, Granelli-Piperno A, Pope M, Trumpfheller C, Ignatius R, et al.
(2003) The interaction of immunodeficiency viruses with dendritic cells. Curr
Top Microbiol Immunol 276: 1–30.
18. Cameron PU, Freudenthal PS, Barker JM, Gezelter S, Inaba K, et al. (1992)
Dendritic cells exposed to human immunodeficiency virus type-1 transmit a
vigorous cytopathic infection to CD4+ T cells. Science 257: 383–387.
19. Pope M, Betjes MG, Romani N, Hirmand H, Cameron PU, et al. (1994)
Conjugates of dendritic cells and memory T lymphocytes from skin facilitate
productive infection with HIV-1. Cell 78: 389–398.
20. Kadowaki N, Ho S, Antonenko S, Malefyt RW, Kastelein RA, et al. (2001)
Subsets of human dendritic cell precursors express different toll-like receptors
and respond to different microbial antigens. J Exp Med 194: 863–869.
21. Poli G, Kinter A, Justement JS, Kehrl JH, Bressler P, et al. (1990) Tumor
necrosis factor alpha functions in an autocrine manner in the induction of
human immunodeficiency virus expression. Proc Natl Acad Sci U S A 87:
782–785.
22. Poli G, Bressler P, Kinter A, Duh E, Timmer WC, et al. (1990) Interleukin 6
induces human immunodeficiency virus expression in infected monocytic cells
alone and in synergy with tumor necrosis factor alpha by transcriptional and
post-transcriptional mechanisms. J Exp Med 172: 151–158.
23. Dong C, Janas AM, Wang JH, Olson WJ, Wu L (2007) Characterization of
human immunodeficiency virus type 1 replication in immature and mature
PPARc and LXR Inhibit DC-Mediated HIV-1 trans-Infection
PLoS Pathogens | www.plospathogens.org 14 July 2010 | Volume 6 | Issue 7 | e1000981
dendritic cells reveals dissociable cis- and trans-infection. J Virol 81:
11352–11362.
24. Wang JH, Janas AM, Olson WJ, Wu L (2007) Functionally distinct
transmission of human immunodeficiency virus type 1 mediated by immature
and mature dendritic cells. J Virol 81: 8933–8943.
25. Izquierdo-Useros N, Blanco J, Erkizia I, Fernandez-Figueras MT, Borras FE,
et al. (2007) Maturation of blood-derived dendritic cells enhances human
immunodeficiency virus type 1 capture and transmission. J Virol 81:
7559–7570.
26. Harman AN, Wilkinson J, Bye CR, Bosnjak L, Stern JL, et al. (2006) HIV
induces maturation of monocyte-derived dendritic cells and Langerhans cells.
J Immunol 177: 7103–7113.
27. Shi GX, Harrison K, Han SB, Moratz C, Kehrl JH (2004) Toll-like receptor
signaling alters the expression of regulator of G protein signaling proteins in
dendritic cells: implications for G protein-coupled receptor signaling. J Immunol
172: 5175–5184.
28. Glass CK, Ogawa S (2006) Combinatorial roles of nuclear receptors in
inflammation and immunity. Nat Rev Immunol 6: 44–55.
29. Castrillo A, Tontonoz P (2004) Nuclear receptors in macrophage biology: at
the crossroads of lipid metabolism and inflammation. Annu Rev Cell Dev Biol
20: 455–480.
30. Jiang C, Ting AT, Seed B (1998) PPAR-gamma agonists inhibit production of
monocyte inflammatory cytokines. Nature 391: 82–86.
31. Ricote M, Li AC, Willson TM, Kelly CJ, Glass CK (1998) The peroxisome
proliferator-activated receptor-gamma is a negative regulator of macrophage
activation. Nature 391: 79–82.
32. Joseph SB, Castrillo A, Laffitte BA, Mangelsdorf DJ, Tontonoz P (2003)
Reciprocal regulation of inflammation and lipid metabolism by liver X
receptors. Nat Med 9: 213–219.
33. Castrillo A, Joseph SB, Vaidya SA, Haberland M, Fogelman AM, et al. (2003)
Crosstalk between LXR and toll-like receptor signaling mediates bacterial and
viral antagonism of cholesterol metabolism. Mol Cell 12: 805–816.
34. Ogawa S, Lozach J, Benner C, Pascual G, Tangirala RK, et al. (2005)
Molecular determinants of crosstalk between nuclear receptors and toll-like
receptors. Cell 122: 707–721.
35. Walcher D, Kummel A, Kehrle B, Bach H, Grub M, et al. (2006) LXR
activation reduces proinflammatory cytokine expression in human CD4-
positive lymphocytes. Arterioscler Thromb Vasc Biol 26: 1022–1028.
36. Appel S, Mirakaj V, Bringmann A, Weck MM, Grunebach F, et al. (2005)
PPAR-gamma agonists inhibit toll-like receptor-mediated activation of
dendritic cells via the MAP kinase and NF-kappaB pathways. Blood 106:
3888–3894.
37. Piraino G, Cook JA, O’Connor M, Hake PW, Burroughs TJ, et al. (2006)
Synergistic effect of peroxisome proliferator activated receptor-gamma and
liver X receptor-alpha in the regulation of inflammation in macrophages.
Shock 26: 146–153.
38. Ghisletti S, Huang W, Ogawa S, Pascual G, Lin ME, et al. (2007) Parallel
SUMOylation-dependent pathways mediate gene- and signal-specific transre-
pression by LXRs and PPARgamma. Mol Cell 25: 57–70.
39. Chawla A, Boisvert WA, Lee CH, Laffitte BA, Barak Y, et al. (2001) A PPAR
gamma-LXR-ABCA1 pathway in macrophages is involved in cholesterol efflux
and atherogenesis. Mol Cell 7: 161–171.
40. Akiyama TE, Sakai S, Lambert G, Nicol CJ, Matsusue K, et al. (2002)
Conditional disruption of the peroxisome proliferator-activated receptor
gamma gene in mice results in lowered expression of ABCA1, ABCG1, and
apoE in macrophages and reduced cholesterol efflux. Mol Cell Biol 22:
2607–2619.
41. Venkateswaran A, Laffitte BA, Joseph SB, Mak PA, Wilpitz DC, et al. (2000)
Control of cellular cholesterol efflux by the nuclear oxysterol receptor LXR
alpha. Proc Natl Acad Sci U S A 97: 12097–12102.
42. Liao Z, Cimakasky LM, Hampton R, Nguyen DH, Hildreth JE (2001) Lipid
rafts and HIV pathogenesis: host membrane cholesterol is required for infection
by HIV type 1. AIDS Res Hum Retroviruses 17: 1009–1019.
43. Guyader M, Kiyokawa E, Abrami L, Turelli P, Trono D (2002) Role for
human immunodeficiency virus type 1 membrane cholesterol in viral
internalization. J Virol 76: 10356–10364.
44. Graham DR, Chertova E, Hilburn JM, Arthur LO, Hildreth JE (2003)
Cholesterol depletion of human immunodeficiency virus type 1 and simian
immunodeficiency virus with beta-cyclodextrin inactivates and permeabilizes
the virions: evidence for virion-associated lipid rafts. J Virol 77: 8237–8248.
45. Liao Z, Graham DR, Hildreth JE (2003) Lipid rafts and HIV pathogenesis:
virion-associated cholesterol is required for fusion and infection of susceptible
cells. AIDS Res Hum Retroviruses 19: 675–687.
46. Popik W, Alce TM (2004) CD4 receptor localized to non-raft membrane
microdomains supports HIV-1 entry. Identification of a novel raft localization
marker in CD4. J Biol Chem 279: 704–712.
47. Nguyen DH, Hildreth JE (2000) Evidence for budding of human immunode-
ficiency virus type 1 selectively from glycolipid-enriched membrane lipid rafts.
J Virol 74: 3264–3272.
48. Ono A, Freed EO (2001) Plasma membrane rafts play a critical role in HIV-1
assembly and release. Proc Natl Acad Sci U S A 98: 13925–13930.
49. Manes S, del Real G, Lacalle RA, Lucas P, Gomez-Mouton C, et al. (2000)
Membrane raft microdomains mediate lateral assemblies required for HIV-1
infection. EMBO Rep 1: 190–196.
50. Carter GC, Bernstone L, Sangani D, Bee JW, Harder T, et al. (2009) HIV
entry in macrophages is dependent on intact lipid rafts. Virology 386: 192–202.
51. Gummuluru S, Rogel M, Stamatatos L, Emerman M (2003) Binding of human
immunodeficiency virus type 1 to immature dendritic cells can occur
independently of DC-SIGN and mannose binding C-type lectin receptors via
a cholesterol-dependent pathway. J Virol 77: 12865–12874.
52. Gosset P, Charbonnier AS, Delerive P, Fontaine J, Staels B, et al. (2001)
Peroxisome proliferator-activated receptor gamma activators affect the
maturation of human monocyte-derived dendritic cells. Eur J Immunol 31:
2857–2865.
53. Straus DS, Glass CK (2007) Anti-inflammatory actions of PPAR ligands: new
insights on cellular and molecular mechanisms. Trends Immunol 28: 551–558.
54. Sallusto F, Schaerli P, Loetscher P, Schaniel C, Lenig D, et al. (1998) Rapid
and coordinated switch in chemokine receptor expression during dendritic cell
maturation. Eur J Immunol 28: 2760–2769.
55. Baribaud F, Doms RW, Pohlmann S (2002) The role of DC-SIGN and DC-
SIGNR in HIV and Ebola virus infection: can potential therapeutics block
virus transmission and dissemination? Expert Opin Ther Targets 6: 423–431.
56. Wiley RD, Gummuluru S (2006) Immature dendritic cell-derived exosomes
can mediate HIV-1 trans infection. Proc Natl Acad Sci U S A 103: 738–743.
57. Cavrois M, Neidleman J, Kreisberg JF, Greene WC (2007) In vitro derived
dendritic cells trans-infect CD4 T cells primarily with surface-bound HIV-1
virions. PLoS Pathog 3: e4.
58. Turville SG, Arthos J, Donald KM, Lynch G, Naif H, et al. (2001) HIV gp120
receptors on human dendritic cells. Blood 98: 2482–2488.
59. Bashirova AA, Geijtenbeek TB, van Duijnhoven GC, van Vliet SJ, Eilering JB,
et al. (2001) A dendritic cell-specific intercellular adhesion molecule 3-grabbing
nonintegrin (DC-SIGN)-related protein is highly expressed on human liver
sinusoidal endothelial cells and promotes HIV-1 infection. J Exp Med 193:
671–678.
60. Pohlmann S, Soilleux EJ, Baribaud F, Leslie GJ, Morris LS, et al. (2001) DC-
SIGNR, a DC-SIGN homologue expressed in endothelial cells, binds to human
and simian immunodeficiency viruses and activates infection in trans. Proc Natl
Acad Sci U S A 98: 2670–2675.
61. Nguyen DG, Hildreth JE (2003) Involvement of macrophage mannose receptor
in the binding and transmission of HIV by macrophages. Eur J Immunol 33:
483–493.
62. Sabado RL, Babcock E, Kavanagh DG, Tjomsland V, Walker BD, et al. (2007)
Pathways utilized by dendritic cells for binding, uptake, processing and
presentation of antigens derived from HIV-1. Eur J Immunol 37: 1752–1763.
63. Patel M, Yanagishita M, Roderiquez G, Bou-Habib DC, Oravecz T, et al.
(1993) Cell-surface heparan sulfate proteoglycan mediates HIV-1 infection of
T-cell lines. AIDS Res Hum Retroviruses 9: 167–174.
64. Saphire AC, Bobardt MD, Zhang Z, David G, Gallay PA (2001) Syndecans
serve as attachment receptors for human immunodeficiency virus type 1 on
macrophages. J Virol 75: 9187–9200.
65. de Witte L, Bobardt M, Chatterji U, Degeest G, David G, et al. (2007)
Syndecan-3 is a dendritic cell-specific attachment receptor for HIV-1. Proc
Natl Acad Sci U S A 104: 19464–19469.
66. Bhat S, Spitalnik SL, Gonzalez-Scarano F, Silberberg DH (1991) Galactosyl
ceramide or a derivative is an essential component of the neural receptor for
human immunodeficiency virus type 1 envelope glycoprotein gp120. Proc Natl
Acad Sci U S A 88: 7131–7134.
67. Hammache D, Pieroni G, Yahi N, Delezay O, Koch N, et al. (1998) Specific
interaction of HIV-1 and HIV-2 surface envelope glycoproteins with
monolayers of galactosylceramide and ganglioside GM3. J Biol Chem 273:
7967–7971.
68. Hug P, Lin HM, Korte T, Xiao X, Dimitrov DS, et al. (2000)
Glycosphingolipids promote entry of a broad range of human immunodefi-
ciency virus type 1 isolates into cell lines expressing CD4, CXCR4, and/or
CCR5. J Virol 74: 6377–6385.
69. Puri A, Hug P, Jernigan K, Barchi J, Kim HY, et al. (1998) The neutral
glycosphingolipid globotriaosylceramide promotes fusion mediated by a CD4-
dependent CXCR4-utilizing HIV type 1 envelope glycoprotein. Proc Natl
Acad Sci U S A 95: 14435–14440.
70. Nehete PN, Vela EM, Hossain MM, Sarkar AK, Yahi N, et al. (2002) A post-
CD4-binding step involving interaction of the V3 region of viral gp120 with
host cell surface glycosphingolipids is common to entry and infection by diverse
HIV-1 strains. Antiviral Res 56: 233–251.
71. Puigdomenech I, Massanella M, Izquierdo-Useros N, Ruiz-Hernandez R,
Curriu M, et al. (2008) HIV transfer between CD4 T cells does not require
LFA-1 binding to ICAM-1 and is governed by the interaction of HIV envelope
glycoprotein with CD4. Retrovirology 5: 32.
72. Hatch SC, Archer J, Gummuluru S (2009) Glycosphingolipid composition of
human immunodeficiency virus type 1 (HIV-1) particles is a crucial
determinant for dendritic cell-mediated HIV-1 trans-infection. J Virol 83:
3496–3506.
73. Izquierdo-Useros N, Naranjo-Gomez M, Archer J, Hatch SC, Erkizia I, et al.
(2009) Capture and transfer of HIV-1 particles by mature dendritic cells
converges with the exosome-dissemination pathway. Blood 113: 2732–2741.
74. Bavari S, Bosio CM, Wiegand E, Ruthel G, Will AB, et al. (2002) Lipid raft
microdomains: a gateway for compartmentalized trafficking of Ebola and
Marburg viruses. J Exp Med 195: 593–602.
PPARc and LXR Inhibit DC-Mediated HIV-1 trans-Infection
PLoS Pathogens | www.plospathogens.org 15 July 2010 | Volume 6 | Issue 7 | e1000981
75. Yonezawa A, Cavrois M, Greene WC (2005) Studies of ebola virus
glycoprotein-mediated entry and fusion by using pseudotyped human
immunodeficiency virus type 1 virions: involvement of cytoskeletal proteins
and enhancement by tumor necrosis factor alpha. J Virol 79: 918–926.
76. Popik W, Alce TM, Au WC (2002) Human immunodeficiency virus type 1 uses
lipid raft-colocalized CD4 and chemokine receptors for productive entry into
CD4(+) T cells. J Virol 76: 4709–4722.
77. Chinetti G, Lestavel S, Bocher V, Remaley AT, Neve B, et al. (2001) PPAR-
alpha and PPAR-gamma activators induce cholesterol removal from human
macrophage foam cells through stimulation of the ABCA1 pathway. Nat Med
7: 53–58.
78. Wasserheit JN (1992) Epidemiological synergy. Interrelationships between
human immunodeficiency virus infection and other sexually transmitted
diseases. Sex Transm Dis 19: 61–77.
79. Royce RA, Sena A, Cates W, Jr., Cohen MS (1997) Sexual transmission of
HIV. N Engl J Med 336: 1072–1078.
80. Fleming DT, Wasserheit JN (1999) From epidemiological synergy to public
health policy and practice: the contribution of other sexually transmitted
diseases to sexual transmission of HIV infection. Sex Transm Infect 75: 3–17.
81. Hester RA, Kennedy SB (2003) Candida infection as a risk factor for HIV
transmission. J Womens Health (Larchmt) 12: 487–494.
82. Celum C, Levine R, Weaver M, Wald A (2004) Genital herpes and human
immunodeficiency virus: double trouble. Bull World Health Organ 82:
447–453.
83. Galvin SR, Cohen MS (2004) The role of sexually transmitted diseases in HIV
transmission. Nat Rev Microbiol 2: 33–42.
84. Haase AT (2005) Perils at mucosal front lines for HIV and SIV and their hosts.
Nat Rev Immunol 5: 783–792.
85. Wu L (2008) Biology of HIV Mucosal Transmission. Curr Opin HIV AIDS 3:
534–540.
86. Bouschbacher M, Bomsel M, Verronese E, Gofflo S, Ganor Y, et al. (2008)
Early events in HIV transmission through a human reconstructed vaginal
mucosa. Aids 22: 1257–1266.
87. Hladik F, McElrath MJ (2008) Setting the stage: host invasion by HIV. Nat Rev
Immunol 8: 447–457.
88. Lore K, Sonnerborg A, Olsson J, Patterson BK, Fehniger TE, et al. (1999)
HIV-1 exposed dendritic cells show increased pro-inflammatory cytokine
production but reduced IL-1ra following lipopolysaccharide stimulation. Aids
13: 2013–2021.
89. Equils O, Schito ML, Karahashi H, Madak Z, Yarali A, et al. (2003) Toll-like
receptor 2 (TLR2) and TLR9 signaling results in HIV-long terminal repeat
trans-activation and HIV replication in HIV-1 transgenic mouse spleen cells:
implications of simultaneous activation of TLRs on HIV replication. J Immunol
170: 5159–5164.
90. Zhang J, Li G, Bafica A, Pantelic M, Zhang P, et al. (2005) Neisseria
gonorrhoeae enhances infection of dendritic cells by HIV type 1. J Immunol
174: 7995–8002.
91. de Jong MA, de Witte L, Oudhoff MJ, Gringhuis SI, Gallay P, et al. (2008)
TNF-alpha and TLR agonists increase susceptibility to HIV-1 transmission by
human Langerhans cells ex vivo. J Clin Invest 118: 3440–3452.
92. Thibault S, Fromentin R, Tardif MR, Tremblay MJ (2009) TLR2 and TLR4
triggering exerts contrasting effects with regard to HIV-1 infection of human
dendritic cells and subsequent virus transfer to CD4+ T cells. Retrovirology 6:
42.
93. Turville SG, Santos JJ, Frank I, Cameron PU, Wilkinson J, et al. (2004)
Immunodeficiency virus uptake, turnover, and 2-phase transfer in human
dendritic cells. Blood 103: 2170–2179.
94. Garcia E, Pion M, Pelchen-Matthews A, Collinson L, Arrighi JF, et al. (2005)
HIV-1 trafficking to the dendritic cell-T-cell infectious synapse uses a pathway
of tetraspanin sorting to the immunological synapse. Traffic 6: 488–501.
95. Yu HJ, Reuter MA, McDonald D (2008) HIV traffics through a specialized,
surface-accessible intracellular compartment during trans-infection of T cells by
mature dendritic cells. PLoS Pathog 4: e1000134.
96. Chun TW, Engel D, Mizell SB, Ehler LA, Fauci AS (1998) Induction of HIV-1
replication in latently infected CD4+ T cells using a combination of cytokines.
J Exp Med 188: 83–91.
97. McGowan I, Elliott J, Fuerst M, Taing P, Boscardin J, et al. (2004) Increased
HIV-1 mucosal replication is associated with generalized mucosal cytokine
activation. J Acquir Immune Defic Syndr 37: 1228–1236.
98. Narimatsu R, Wolday D, Patterson BK (2005) IL-8 increases transmission of
HIV type 1 in cervical explant tissue. AIDS Res Hum Retroviruses 21:
228–233.
99. Carreno MP, Krieff C, Irinopoulou T, Kazatchkine MD, Belec L (2002)
Enhanced transcytosis of R5-tropic human immunodeficiency virus across tight
monolayer of polarized human endometrial cells under pro-inflammatory
conditions. Cytokine 20: 289–294.
100. Lane BR, Lore K, Bock PJ, Andersson J, Coffey MJ, et al. (2001) Interleukin-8
stimulates human immunodeficiency virus type 1 replication and is a potential
new target for antiretroviral therapy. J Virol 75: 8195–8202.
101. del Real G, Jimenez-Baranda S, Mira E, Lacalle RA, Lucas P, et al. (2004)
Statins inhibit HIV-1 infection by down-regulating Rho activity. J Exp Med
200: 541–547.
102. Larrede S, Quinn CM, Jessup W, Frisdal E, Olivier M, et al. (2009) Stimulation
of Cholesterol Efflux by LXR Agonists in Cholesterol-Loaded Human
Macrophages Is ABCA1-Dependent but ABCG1-Independent. Arterioscler
Thromb Vasc Biol.
103. Groot F, Welsch S, Sattentau QJ (2008) Efficient HIV-1 transmission from
macrophages to T cells across transient virological synapses. Blood 111:
4660–4663.
104. Gousset K, Ablan SD, Coren LV, Ono A, Soheilian F, et al. (2008) Real-time
visualization of HIV-1 GAG trafficking in infected macrophages. PLoS Pathog
4: e1000015.
105. Jolly C, Sattentau QJ (2005) Human immunodeficiency virus type 1 virological
synapse formation in T cells requires lipid raft integrity. J Virol 79:
12088–12094.
106. McDonald D, Wu L, Bohks SM, KewalRamani VN, Unutmaz D, et al. (2003)
Recruitment of HIV and its receptors to dendritic cell-T cell junctions. Science
300: 1295–1297.
107. Rudnicka D, Feldmann J, Porrot F, Wietgrefe S, Guadagnini S, et al. (2009)
Simultaneous cell-to-cell transmission of human immunodeficiency virus to
multiple targets through polysynapses. J Virol 83: 6234–6246.
108. Chen P, Hubner W, Spinelli MA, Chen BK (2007) Predominant mode of
human immunodeficiency virus transfer between T cells is mediated by
sustained Env-dependent neutralization-resistant virological synapses. J Virol
81: 12582–12595.
109. Moris A, Pajot A, Blanchet F, Guivel-Benhassine F, Salcedo M, et al. (2006)
Dendritic cells and HIV-specific CD4+ T cells: HIV antigen presentation, T-
cell activation, and viral transfer. Blood 108: 1643–1651.
110. Granelli-Piperno A, Shimeliovich I, Pack M, Trumpfheller C, Steinman RM
(2006) HIV-1 selectively infects a subset of nonmaturing BDCA1-positive
dendritic cells in human blood. J Immunol 176: 991–998.
111. Blauvelt A, Asada H, Saville MW, Klaus-Kovtun V, Altman DJ, et al. (1997)
Productive infection of dendritic cells by HIV-1 and their ability to capture
virus are mediated through separate pathways. J Clin Invest 100: 2043–2053.
112. Granelli-Piperno A, Delgado E, Finkel V, Paxton W, Steinman RM (1998)
Immature dendritic cells selectively replicate macrophagetropic (M-tropic)
human immunodeficiency virus type 1, while mature cells efficiently transmit
both M- and T-tropic virus to T cells. J Virol 72: 2733–2737.
113. Skolnik PR, Rabbi MF, Mathys JM, Greenberg AS (2002) Stimulation of
peroxisome proliferator-activated receptors alpha and gamma blocks HIV-1
replication and TNFalpha production in acutely infected primary blood cells,
chronically infected U1 cells, and alveolar macrophages from HIV-infected
subjects. J Acquir Immune Defic Syndr 31: 1–10.
114. Hayes MM, Lane BR, King SR, Markovitz DM, Coffey MJ (2002) Peroxisome
proliferator-activated receptor gamma agonists inhibit HIV-1 replication in
macrophages by transcriptional and post-transcriptional effects. J Biol Chem
277: 16913–16919.
115. Potula R, Ramirez SH, Knipe B, Leibhart J, Schall K, et al. (2008) Peroxisome
proliferator-activated receptor-gamma activation suppresses HIV-1 replication
in an animal model of encephalitis. Aids 22: 1539–1549.
116. Nguyen DH, Taub D (2002) CXCR4 function requires membrane cholesterol:
implications for HIV infection. J Immunol 168: 4121–4126.
PPARc and LXR Inhibit DC-Mediated HIV-1 trans-Infection
PLoS Pathogens | www.plospathogens.org 16 July 2010 | Volume 6 | Issue 7 | e1000981
